Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with  myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

ILIvana LotesoriereFLFederico LussanaCPCristina Papayannidis

Discussion

Loading...

Member takes

Overview

This retrospective analysis demonstrates TP53 mutations affect treatment outcomes in acute myeloid leukemia, suggesting CPX-351 may serve as a bridge to transplantation.

Key Points

  • This research assesses the role of CPX-351 in facilitating stem cell transplantation for patients with TP53 mutated acute myeloid leukemia.
  • Conducted a large retrospective analysis of AML patients treated with CPX-351 between 2019 and 2021.
  • Evaluated the presence of TP53 mutations and their impact on treatment outcomes and overall survival.
  • Used Sanger and Next Generation Sequencing techniques to analyze mutation status.
  • The study identified TP53 mutations in 15% of patients, impacting prognosis and treatment response.
  • Overall survival was lower for TP53 mutated patients compared to wild-type, highlighting the prognostic relevance of mutations.
  • Del(17p) was associated with significantly poorer survival outcomes in the TP53m cohort.

Cite This Study

Lotesoriere et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d39dhttps://doi.org/10.1182/blood-2025-4608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial2026 · 7 citations
  2. 2Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.2025
  3. 3Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  4. 4Real‐world analysis of <scp>CPX</scp> ‐351 in <scp>AML</scp> ‐ <scp>MR</scp> : A multicentre study from the <scp>MARROW</scp> consortium2025 · 1 citations
  5. 5Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations